Antimicrobial resistance in bacterial sexually transmitted infections

  30 March 2022

Antimicrobial resistance (AMR) in bacterial sexually transmitted infections (STIs) is a global public health concern. Neisseria gonorrhoeae and Mycoplasma genitalium are emerging ‘superbugs’ that have developed AMR to all antimicrobials used in their treatment, and treatment failures have been reported. There is a very real threat that these infections could become untreatable in the future. Although syphilis and chlamydia infections are easily treated with first-line antimicrobials, macrolide resistance has emerged in Treponema pallidum, and there is a concern that AMR could potentially develop in Chlamydia trachomatis.

 

Further reading: Medicine
Author(s): Rachel Pitt, Helen Fifer
Healthy Patients  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!